6533b83afe1ef96bd12a7b12

RESEARCH PRODUCT

Cytokeratin expression patterns in low-grade papillary urothelial neoplasms of the urinary bladder.

Manuel Gil-salomRafael VillamónSamuel NavarroAntonio Llombart-boschDavid Ramos

subject

AdultMaleCancer ResearchPathologymedicine.medical_specialtyKeratin-20Disease-Free SurvivalImmunoenzyme TechniquesCytokeratinAntigenIntermediate Filament ProteinsBladder NeoplasmCarcinomamedicineBiomarkers TumorHumansNeoplasm InvasivenessAgedNeoplasm StagingRetrospective StudiesAged 80 and overUrinary bladderbusiness.industryKeratin 20CancerMiddle Agedmedicine.diseasePrognosisCarcinoma PapillarySurvival Ratemedicine.anatomical_structureOncologyUrinary Bladder NeoplasmsDisease ProgressionImmunohistochemistryKeratinsFemaleNeoplasm Recurrence LocalbusinessFollow-Up Studies

description

BACKGROUND The differential expression patterns of cytokeratin 20 (CK20) and 34βE12 antigen in low-grade papillary urothelial tumors of the bladder are discussed. METHODS A retrospective study of 120 patients with low-grade papillary bladder tumors (45 neoplasms of low malignant potential and 75 low-grade WHO G1 carcinomas) was performed. All tumors were graded in accordance with the 1998 World Health Organization/International Society of Urological Pathology (WHO/ISUP) and 1999 WHO classifications. The mean follow-up was 76.6 months (range, 36–168 mos), considering for prognostic purposes the time to first recurrence, or relapse-free interval (RFI), and the total number of recurrent patients. Immunohistochemically, normal or abnormal CK20 and 34βE12 antigen expression patterns were determined for each patient. CK20 (clone IT-Ks) and a high-molecular weight cytokeratin (clone 34βE12) were the monoclonal antibodies used in the immunohistochemical study. RESULTS Seventy-seven of 120 patients (64.2%) experienced a recurrence during follow-up. In recurrence prediction, the differential expression pattern of both cytokeratins showed a high sensitivity (76.6% for CK20 and 80.5% for 34βE12 antigen) and a high positive predictive value (85.5% for CK20 and 75.6% for 34βE12 antigen), although specificity was higher for CK20 (76.7%) than it was for 34βE12 antigen (53.4%). Independent of adjuvant intravesical chemotherapy, these 2 markers showed a strong statistical correlation (p < 0.001) in univariate studies with both the prediction of disease recurrences and RFI. CONCLUSIONS CK20 and 34βE12 antigen have proved to be strong predictive markers of disease recurrences when considering different topographic expression profiles, and, in the authors' opinion, these profiles could be incorporated into follow-up clinicopathologic strategies. Cancer 2003;97:1876–83. © 2003 American Cancer Society. DOI 10.1002/cncr.11265

yearjournalcountryeditionlanguage
2003-04-15Cancer
10.1002/cncr.11265https://pubmed.ncbi.nlm.nih.gov/12673713